Laman UtamaLSI • FRA
add
CK Life Sciences Intl (Holdings) Inc
Tutup sebelumnya
€0.090
Julat hari
€0.090 - €0.090
Julat tahun
€0.033 - €0.091
Permodalan pasaran
8.07B HKD
Nisbah P/E
-
Hasil dividen
-
Pertukaran utama
HKG
Berita pasaran
Invezz
2 hari lalu
Amaran risiko: ‘kemelesetan sederhana’ boleh menjejaskan tahap S&P 500 kepada 3,700
0.74%
Kewangan
Penyata Pendapatan
Hasil
Pendapatan bersih
| (HKD) | Dis 2024info | Perubahan T/T |
|---|---|---|
Hasil | 1.44B | 5.22% |
Perbelanjaan pengendalian | 484.04J | 31.22% |
Pendapatan bersih | -63.78J | -548.74% |
Margin untung bersih | -4.42 | -513.89% |
Pendapatan bagi setiap syer | — | — |
EBITDA | 4.85J | -95.35% |
Kadar cukai berkesan | -32.21% | — |
Kunci Kira-kira
Jumlah aset
Jumlah liabiliti
| (HKD) | Dis 2024info | Perubahan T/T |
|---|---|---|
Pelaburan tunai dan jangka pendek | 571.21J | -15.52% |
Jumlah aset | 10.79B | -4.08% |
Jumlah liabiliti | 7.28B | 3.10% |
Jumlah ekuiti | 3.51B | — |
Syer tertunggak | 9.61B | — |
Harga kepada buku | 0.24 | — |
Pulangan pada aset | -0.87% | — |
Pulangan pada modal | -0.97% | — |
Aliran Tunai
Perubahan bersih dalam tunai
| (HKD) | Dis 2024info | Perubahan T/T |
|---|---|---|
Pendapatan bersih | -63.78J | -548.74% |
Tunai daripada operasi | 104.07J | -52.01% |
Tunai daripada pelaburan | -441.00K | 98.29% |
Tunai daripada pembiayaan | -93.26J | 12.31% |
Perubahan bersih dalam tunai | 2.38J | -97.21% |
Aliran tunai bebas | 4.79J | 136.38% |
Perihal
CK Life Sciences International Inc., or CK Life Sciences, is a subsidiary of CK Hutchison Holdings. It is engaged in research and development, commercialization, marketing and sale of biotechnology products. The chairman is Mr. Victor Li, the elder son of Mr. Li Ka-shing, the chairman of Cheung Kong Holdings.
It was established in 2000 and listed on the Hong Kong Stock Exchange via Growth Enterprise Market in 2002. It was transferred to Main Board of the Hong Kong Stock Exchange in 2008.
CK Life Sciences has operations in Australia, and in 2012 acquired an Australian salt company as part of its expansion into the agricultural sector.
The company divested its Canadian subsidiary WEX Pharmaceuticals to Virios Therapeutics for $100 million in October 2024. Wikipedia
CEO
Diasaskan
2000
Tapak web
Pekerja
2,033
